Please try another search
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company’s product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Yanmin Tang | 49 | 2021 | Non-Executive Director |
Yao-Chang Xu | 65 | 2016 | Founder, Chairman of the Board & CEO |
Hongbin Sun | 47 | 2021 | Independent Non-Executive Director |
Lei Wang | 50 | 2021 | Independent Non-Executive Director |
Piaoyang Sun | 65 | 2021 | Independent Non-Executive Director |
Zhui Chen | 49 | 2016 | Co-Founder, Senior VP of Biology, Chief Scientific Officer & Executive Director |
Hongping Yu | 56 | 2016 | Co-Founder, Joint Company Secretary, Senior VP-Chemistry, Chief Scientific Officer & Exe. Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review